PURPOSE: We studied the incidence of chromosomal anomalies in patients with cryptorchidism and hypospadias to determine the value of routine karyotyping in this population. MATERIALS AND METHODS: Blood samples from 984 patients with cryptorchidism and/or hypospadias were studied for chromosome analysis. RESULTS: Chromosomal anomalies were detected in 27 of the 916 patients (2.94%) with cryptorchidism and in 7 of the 100 (7%) with hypospadias. There were chromosomal aberrations in 13 of the 706 patients (1.84%) with isolated cryptorchidism (no additional congenital abnormalities) and in 14 of the 210 (6.67%) with cryptorchidism with associated anomalies. We identified normal karyotypes in 26 patients with isolated hypospadias, although 7 of the 74 (9.46%) with hypospadias and additional abnormalities had chromosomal aberrations. CONCLUSIONS: It is important to perform karyotyping in these patients, mainly when they show associated abnormalities other than cryptorchidism or hypospadias. However, cost-benefit analysis must be done in each case.
PURPOSE: We studied the incidence of chromosomal anomalies in patients with cryptorchidism and hypospadias to determine the value of routine karyotyping in this population. MATERIALS AND METHODS: Blood samples from 984 patients with cryptorchidism and/or hypospadias were studied for chromosome analysis. RESULTS:Chromosomal anomalies were detected in 27 of the 916 patients (2.94%) with cryptorchidism and in 7 of the 100 (7%) with hypospadias. There were chromosomal aberrations in 13 of the 706 patients (1.84%) with isolated cryptorchidism (no additional congenital abnormalities) and in 14 of the 210 (6.67%) with cryptorchidism with associated anomalies. We identified normal karyotypes in 26 patients with isolated hypospadias, although 7 of the 74 (9.46%) with hypospadias and additional abnormalities had chromosomal aberrations. CONCLUSIONS: It is important to perform karyotyping in these patients, mainly when they show associated abnormalities other than cryptorchidism or hypospadias. However, cost-benefit analysis must be done in each case.
Authors: Mounia Tannour-Louet; Shuo Han; Sean T Corbett; Jean-Francois Louet; Svetlana Yatsenko; Lindsay Meyers; Chad A Shaw; Sung-Hae L Kang; Sau Wai Cheung; Dolores J Lamb Journal: PLoS One Date: 2010-10-26 Impact factor: 3.240
Authors: S Faisal Ahmed; John C Achermann; Wiebke Arlt; Adam H Balen; Gerry Conway; Zoe L Edwards; Sue Elford; Ieuan A Hughes; Louise Izatt; Nils Krone; Harriet L Miles; Stuart O'Toole; Les Perry; Caroline Sanders; Margaret Simmonds; A Michael Wallace; Andrew Watt; Debbie Willis Journal: Clin Endocrinol (Oxf) Date: 2011-07 Impact factor: 3.478
Authors: S Faisal Ahmed; John C Achermann; Wiebke Arlt; Adam Balen; Gerry Conway; Zoe Edwards; Sue Elford; Ieuan A Hughes; Louise Izatt; Nils Krone; Harriet Miles; Stuart O'Toole; Les Perry; Caroline Sanders; Margaret Simmonds; Andrew Watt; Debbie Willis Journal: Clin Endocrinol (Oxf) Date: 2015-08-13 Impact factor: 3.478